ENZN Stock Overview
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enzon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.088 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.06 |
| Beta | 0.33 |
| 1 Month Change | 4.14% |
| 3 Month Change | 3.41% |
| 1 Year Change | -57.07% |
| 3 Year Change | -85.32% |
| 5 Year Change | -63.26% |
| Change since IPO | -99.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 21.6% | 0.4% | 1.0% |
| 1Y | -57.1% | 0.9% | 21.9% |
Return vs Industry: ENZN underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: ENZN underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ENZN volatility | |
|---|---|
| ENZN Average Weekly Movement | 26.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENZN's share price has been volatile over the past 3 months.
Volatility Over Time: ENZN's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Rick Feinstein | enzon.com |
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
Enzon Pharmaceuticals, Inc. Fundamentals Summary
| ENZN fundamental statistics | |
|---|---|
| Market cap | US$6.53m |
| Earnings (TTM) | US$98.00k |
| Revenue (TTM) | n/a |
66.6x
P/E Ratio0.0x
P/S RatioIs ENZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENZN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$98.00k |
| Earnings | US$98.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENZN perform over the long term?
See historical performance and comparison